Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with measurable, histological diagnosis of hepatocellular carcinoma (HCC) and whose disease is not amenable to surgical or regional therapy.~2. Prior allowed therapy:~   * Surgery including hepatic resection~     1. Minimum of 4 weeks since any surgical procedure.~    2. Patients must have adequately recovered from surgery.~  * Regional therapy~     1. Includes transarterial chemoembolization (TACE), drug-eluting bead \[DEB\]-TACE, percutaneous ethanol injection, radiofrequency/cryo ablation, Yttrium-90 radioembolization.~    2. More than 2 weeks must have lapsed from therapy.~    3. There must be an indicator lesion outside the treated area or clear evidence of progression in the treated lesion, not amenable for further local therapies.~    4. Concomitant sorafenib with regional therapy is allowed as long as no evidence of progression on sorafenib.~  * Prior adjuvant sorafenib is allowed, if completed more than 6 months prior to disease recurrence.~3. Adequate hematological, liver and metabolic organ function.~4. Signed informed consent.~Exclusion Criteria:~1. Patients with mixed histology or fibrolamellar variant.~2. Prior systemic therapy for metastatic disease.~3. Uncontrolled hypertension (HTN).~4. Symptomatic heart failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tivozanib (Type: EXPERIMENTAL): Patients would receive Tivozanib 1.0 mg/day orally, 3 weeks on, one week off, for one cycle starting day 1. If no adverse event is encountered, patients will continue subsequent cycles of Tivozanib 1.5 mg/day orally; 3 weeks on/1 week off, dosing schedule. Patients will continue on treatment until disease progression, unacceptable toxicity, or patient withdrawal from the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).